Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers

Cohen, Adam L.; Piccolo, Stephen R.; Cheng, Luis; Soldi, Rafaella; Han, Bing; Evan Johnson, W.; Bild, Andrea H.
October 2013
BMC Medical Genomics;2013, Vol. 6 Issue 1, p1
Academic Journal
Background: Alterations in epigenetic marks, including methylation or acetylation, are common in human cancers. For many epigenetic pathways, however, direct measures of activity are unknown, making their role in various cancers difficult to assess. Gene expression signatures facilitate the examination of patterns of epigenetic pathway activation across and within human cancer types allowing better understanding of the relationships between these pathways. Methods: We used Bayesian regression to generate gene expression signatures from normal epithelial cells before and after epigenetic pathway activation. Signatures were applied to datasets from TCGA, GEO, CaArray, ArrayExpress, and the cancer cell line encyclopedia. For TCGA data, signature results were correlated with copy number variation and DNA methylation changes. GSEA was used to identify biologic pathways related to the signatures. Results: We developed and validated signatures reflecting downstream effects of enhancer of zeste homolog 2 (EZH2), histone deacetylase(HDAC) 1, HDAC4, sirtuin 1(SIRT1), and DNA methyltransferase 2(DNMT2). By applying these signatures to data from cancer cell lines and tumors in large public repositories, we identify those cancers that have the highest and lowest activation of each of these pathways. Highest EZH2 activation is seen in neuroblastoma, hepatocellular carcinoma, small cell lung cancer, and melanoma, while highest HDAC activity is seen in pharyngeal cancer, kidney cancer, and pancreatic cancer. Across all datasets studied, activation of both EZH2 and HDAC4 is significantly underrepresented. Using breast cancer and glioblastoma as examples to examine intrinsic subtypes of particular cancers, EZH2 activation was highest in luminal breast cancers and proneural glioblastomas, while HDAC4 activation was highest in basal breast cancer and mesenchymal glioblastoma. EZH2 and HDAC4 activation are associated with particular chromosome abnormalities: EZH2 activation with aberrations in genes from the TGF and phosphatidylinositol pathways and HDAC4 activation with aberrations in inflammatory and chemokine related genes. Conclusion: Gene expression patterns can reveal the activation level of epigenetic pathways. Epigenetic pathways define biologically relevant subsets of human cancers. EZH2 activation and HDAC4 activation correlate with growth factor signaling and inflammation, respectively, and represent two distinct states for cancer cells. This understanding may allow us to identify targetable drivers in these cancer subsets.


Related Articles

  • Epigenetic Therapy for Solid Tumors: Highlighting the Impact of Tumor Hypoxia. Ramachandran, Shaliny; Ient, Jonathan; Göttgens, Eva-Leonne; Krieg, Adam J.; Hammond, Ester M. // Genes;Dec2015, Vol. 6 Issue 4, p935 

    In the last few decades, epigenetics has emerged as an exciting new field in development and disease, with a more recent focus towards cancer. Epigenetics has classically referred to heritable patterns of gene expression, primarily mediated through DNA methylation patterns. More recently, it has...

  • Cancer Chemoprevention by Targeting the Epigenome. Huang, Joseph; Plass, Christoph; Gerhäuser, Clarissa // Current Drug Targets;Dec2011, Vol. 12 Issue 13, p1925 

    The term "epigenetics" refers to modifications in gene expression caused by heritable, but potentially reversible, changes in DNA methylation and chromatin structure. Given the fact that epigenetic modifications occur early in carcinogenesis and represent potentially initiating events in cancer...

  • Epigenetics as a Therapeutic Target in Breast Cancer. Connolly, Roisin; Stearns, Vered // Journal of Mammary Gland Biology & Neoplasia;Dec2012, Vol. 17 Issue 3/4, p191 

    Epigenetics refers to alterations in gene expression due to modifications in histone acetylation and DNA methylation at the promoter regions of genes. Unlike genetic mutations, epigenetic alterations are not due to modifications in the gene primary nucleotide sequence. The importance of...

  • The effect of histone deacetylase and DNA methyltransferase inhibitors on expression of androgen receptor gene in androgen-independent prostate cancer cell lines. Fialova, Barbora; Smesny Trtkova, Katerina; Paskova, Lenka; Kolar, Zdenek // Biomedical Papers of the Medical Faculty of Palacky University i;Dec2012, Vol. 156 Issue Supp 3, pS118 

    Introduction. Androgen receptor (AR) expression in prostate cancer (CaP) cells varies due to multiple changes including epigenetic modifications such as DNA methylation and histone deacetylation. DNA methyltransferases and histone deacetylases inhibitors are promising for the treatment of CaP...

  • Epigenetic regulation of regulatory T cells in patients with abdominal aortic aneurysm. Xia, Qian; Zhang, Jian; Han, Yanshuo; Zhang, Xiaoyu; Jiang, Han; Lun, Yu; Wu, Xiaoyu; Gang, Qingwei; Liu, Zhimin; Böckler, Dittmar; Duan, Zhiquan; Xin, Shijie // FEBS Open Bio;Jun2019, Vol. 9 Issue 6, p1137 

    Abdominal arterial aneurysm (AAA) shares many features with autoimmune diseases and appears to be a T‐cell‐mediated process. In addition, certain epigenetic changes, including DNA methylation, are associated with AAA. In this study, we investigated epigenetic modifications in...

  • Epigenetic Mechanisms Underlying the Dynamic Expression of Cancer-Testis Genes, PAGE2, -2B and SPANX-B, during Mesenchymal-to-Epithelial Transition. Yilmaz-Ozcan, Sinem; Sade, Asli; Kucukkaraduman, Baris; Kaygusuz, Yasemin; Senses, Kerem Mert; Banerjee, Sreeparna; Gure, Ali Osmay // PLoS ONE;Sep2014, Vol. 9 Issue 9, p1 

    Cancer-testis (CT) genes are expressed in various cancers but not in normal tissues other than in cells of the germline. Although DNA demethylation of promoter-proximal CpGs of CT genes is linked to their expression in cancer, the mechanisms leading to demethylation are unknown. To elucidate...

  • Genetic syndromes caused by mutations in epigenetic genes. Berdasco, María; Esteller, Manel // Human Genetics;Apr2013, Vol. 132 Issue 4, p359 

    The orchestrated organization of epigenetic factors that control chromatin dynamism, including DNA methylation, histone marks, non-coding RNAs (ncRNAs) and chromatin-remodeling proteins, is essential for the proper function of tissue homeostasis, cell identity and development. Indeed,...

  • The Histone Deacetylase Inhibitor JAHA Down-Regulates pERK and Global DNA Methylation in MDA-MB231 Breast Cancer Cells. Librizzi, Mariangela; Chiarelli, Roberto; Bosco, Liana; Sansook, Supojjanee; Gascon, Jose M.; Spencer, John; Caradonna, Fabio; Luparello, Claudio // Materials (1996-1944);2015, Vol. 8 Issue 10, p7041 

    The histone deacetylase inhibitor N¹-(ferrocenyl)-N8-hydroxyoctanediamide (JAHA) down-regulates extracellular-signal-regulated kinase (ERK) and its activated form in triple-negative MDA-MB231 breast cancer cells after 18 h and up to 30 h of treatment, and to a lesser extent AKT and...

  • A phase 1 trial of the oral DNA methyltransferase inhibitor CC-486 and the histone deacetylase inhibitor romidepsin in advanced solid tumors. Gaillard, Stéphanie L.; Zahurak, Marianna; Sharma, Anup; Durham, Jennifer N.; Reiss, Kim A.; Sartorius‐Mergenthaler, Susan; Downs, Melinda; Anders, Nicole M.; Ahuja, Nita; Rudek, Michelle A.; Azad, Nilofer; Sartorius-Mergenthaler, Susan // Cancer (0008543X);Aug2019, Vol. 125 Issue 16, p2837 

    Background: Epigenetic abnormalities are manifold in all solid tumors and include changes in chromatin configuration and DNA methylation. The authors designed a phase 1 study to evaluate the oral DNA methyltransferase inhibitor CC-486 combined with the histone deacetylase inhibitor...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics